WEBMICA/B molecules are attractive targets for an ADC approach based on their selective expression in a wide range of malignancies while showing restricted expression in healthy tissues. The anti-MICA/B-PBD shows efficacy both in vitro and in vivo, paving the path for further evaluation
Targeting MICA/B with cytotoxic therapeutic antibodies leads to …
WEBOct 27, 2021 · Results: The anti-MICA and MICB antibody MICAB1, a human IgG1 Fc-engineered monoclonal antibody (mAb), displayed potent antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) of MICA/B-expressing tumor cells in vitro.
A phase 1 dose-escalation study to investigate the safety, efficacy ...
WEBMay 31, 2023 · CLN-619 is a humanized MICA/B-specific IgG1 monoclonal antibody designed to prevent the proteolytic release of MICA/B, restoring immune-mediated tumor cell lysis. CLN-619 is expected to have broad anti-tumor activity.
Targeting MICA/B with cytotoxic therapeutic antibodies leads
WEBOct 27, 2021 · Results: The anti-MICA and MICB antibody MICAB1, a human IgG1 Fc-engineered monoclonal antibody (mAb), displayed potent antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) of MICA/B-expressing tumor cells in vitro.
Full article: Engaging natural killer cells for cancer therapy via ...
WEBInnate Pharma recently reported results for the MICA/B targeted ADC MICAB1. The mAb used to generate the ADC was selected due to its ability to stimulate a high level of MICA/B internalization and engineered to be Fc-silent.
A chimeric antigen receptor uniquely recognizing MICA/B stress …
WEBJul 14, 2023 · MICA and MICB (MICA/B) are polyallelic stress proteins expressed on many human tumors. •. Targeting the conserved α3 domain of MICA/B mitigates tumor immune evasion. •. MICA/B-targeting chimeric antigen receptor (CAR) provides broad tumor recognition. •. iPSC-derived NK cells expressing MICA/B CAR and CD16 show potent anti-tumor activity. Summary.
(PDF) Targeting MICA/B with cytotoxic therapeutic ... - ResearchGate
WEBOct 27, 2021 · Results: The anti-MICA and MICB antibody MICAB1, a human IgG1 Fc-engineered monoclonal antibody (mAb), displayed potent antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent...
WEBMICA and the closely related MICB proteins are candidates of choice to be targeted by a cytotoxic therapeutic antibody. We have generated a panel of anti-MICA mAbs with diverse functional properties. Ongoing work aims to choose the best candidate for humanization and further clinical development. Targeting MICA with therapeutic
WEBChemotherapeutic agents upregulate MICA expression. Newly generated anti-MICA mAb display high affinities, are pan-alleles and can mediate direct cytotoxic effect through ADCC and/or CDC and demonstrate in vivo. Associated biomarker strategy: MICA expression on tumor, soluble MICA in serum.
Targeting MICA with therapeutic antibodies for the treatment of …
WEBWe first evaluated MICA/B expression by immunohistochemistry on healthy tissues and tumors to validate these antigens as therapeutic targets. Then, using mouse immunization, we generated a panel of chimeric human IgG1 …
Skip to content